ATLANTA, GA – – (Businesswire – May 1, 2019) – – Holzer & Holzer, LLC is investigating whether certain statements made by Nabriva Therapeutics plc (“Nabriva Therapeutics” or the “Company”)(NASDAQ: NBRV) complied with federal securities laws. On April 30, 2019, Nabriva Therapeutics issued a press release announcing that it received a Complete Response Letter from the FDA requesting that the Company address issues related to facility inspections and manufacturing deficiencies at one of its contract manufacturers. The price of Nabriva Therapeutics’ stock fell following the announcement. If you purchased shares of Nabriva shares and suffered a loss on that investment, you are encouraged to contact Corey D. Holzer, Esq. at email@example.com or Marshall P. Dees, Esq. at firstname.lastname@example.org, or by toll-free telephone at (888) 508-6832 to discuss your legal rights.